Company profile
Veradermics, Incorporated logo

Veradermics, Incorporated

Pipeline5 assets

  • VDPHL01VDPHL01 / Small molecule / Dermatology
    Androgenetic Alopecia (Pattern Hair Loss)
  • VDAAVDAA / Topical small molecule / Dermatology
    Alopecia Areata
  • VDADVDAD / Dermatology
    Atopic Dermatitis
  • VDMCVDMC / Dermatology
    Molluscum Contagiosum
  • VDMN-21VDMN-21 / Immune stimulatory / Microarray / Dermatology
    Warts

Latest news17 items

All news

Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy

NEW HAVEN, Conn. --(BUSINESS WIRE)--Jul. 17, 2026-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study ‘302’ of

Presentation / Abstract • Phase 2/3Oral presentation Fri, Jul 17, 2026, 10:10 AM ET

Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout

VDPHL01, a novel orally-administered extended-release minoxidil formulation, achieved fast onset of hair growth with the majority of study participants reporting improvement in hair coverage as early as Month 2 and consistent treatment effect with approximately 88.9% (once daily) and 90.0%

Trial Results • Phase 2Study 207 topline results Wed, Jul 15, 2026

Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss

Conference call will take place on Wednesday, July 15, 2026 at 8:00 am ET NEW HAVEN, Conn. --(BUSINESS WIRE)--Jul. 14, 2026-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss,

Results Call • Phase 2Results call Wed, Jul 15, 2026, 8:00 AM ET

Veradermics to Present at Upcoming June Investor Conferences

NEW HAVEN, Conn. --(BUSINESS WIRE)--May 28, 2026-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the

Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 at the 2026 World Congress for Hair Research

NEW HAVEN, Conn. --(BUSINESS WIRE)--May 27, 2026-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that topline results from Phase 2/3 ‘302’ Study of

Presentation / Abstract • Phase 2/3Poster presentation Sat, May 30, 2026, 3:00 PM KST

Veradermics Announces Pricing of Upsized Public Offering and Private Placement

NEW HAVEN, Conn. --(BUSINESS WIRE)--Apr. 29, 2026-- Veradermics, Incorporated (“Veradermics”) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the pricing of its upsized public

Veradermics Announces Launch of Public Offering

NEW HAVEN, Conn. --(BUSINESS WIRE)--Apr. 27, 2026-- Veradermics, Incorporated (“Veradermics”) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that it has launched a proposed

Veradermics to Participate in Upcoming March Investor Conferences

NEW HAVEN, Conn. --(BUSINESS WIRE)--Mar. 3, 2026-- Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that management will

Veradermics Announces Pricing of Upsized Initial Public Offering

NEW HAVEN, Conn. --(BUSINESS WIRE)--Feb. 3, 2026-- Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the

Veradermics, Incorporated • Endpoint Arena